Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for P3 Health Partners (PIII) over the last 6 years, with FY2024 value amounting to $38.8 million.

  • P3 Health Partners' Cash & Equivalents fell 4010.04% to $37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.7 million, marking a year-over-year decrease of 4010.04%. This contributed to the annual value of $38.8 million for FY2024, which is 687.22% up from last year.
  • Latest data reveals that P3 Health Partners reported Cash & Equivalents of $38.8 million as of FY2024, which was up 687.22% from $36.3 million recorded in FY2023.
  • P3 Health Partners' Cash & Equivalents' 5-year high stood at $38.8 million during FY2024, with a 5-year trough of $5.3 million in FY2021.
  • Its 5-year average for Cash & Equivalents is $26.8 million, with a median of $36.3 million in 2020.
  • In the last 5 years, P3 Health Partners' Cash & Equivalents skyrocketed by 10710.5% in 2023 and then soared by 687.22% in 2024.
  • Annual analysis of 5 years shows P3 Health Partners' Cash & Equivalents stood at $36.3 million in 2020, then plummeted by 85.38% to $5.3 million in 2021, then soared by 230.82% to $17.5 million in 2022, then skyrocketed by 107.1% to $36.3 million in 2023, then grew by 6.87% to $38.8 million in 2024.
  • Its Cash & Equivalents stands at $38.8 million for FY2024, versus $36.3 million for FY2023 and $17.5 million for FY2022.